HemoShear's Human Disease Model Validated By Takeda NASH Deal

Emerging Company Profile: HemoShear thinks its REVEAL-tx platform can identify novel targets and validate drug candidates better than existing bench research methods. Japan’s Takeda is betting in a new collaboration that HemoShear can deliver novel targets in NASH.

Emerging Company Profile Regular column feature image Version 2

HemoShear LLC obtained both substantial financial backing and validation of its technology platform on Oct. 17 through a collaboration with Takeda Pharmaceutical Co. Ltd. to identify novel targets for non-alcoholic steatohepatitis (NASH).

The deal in a big liver disease indication is an important endorsement for HemoShear's REVEAL-tx disease-modeling platform, which the Charlottesville, Va.-based company created based on a goal to develop better bench research tools than cells in petri dishes or animal models

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Start-Ups & SMEs

More from Business

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By 

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.